Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series
June 22, 2020 09:00 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant
June 19, 2020 06:00 ET
|
Dynavax Technologies Corporation
Preclinical results demonstrated the ability of CpG 1018-adjuvanted SCB-2019 to elicit neutralizing antibodies in multiple animal speciesClover expects to enroll 150 healthy adult and elderly...
Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
June 09, 2020 08:00 ET
|
Dynavax Technologies Corporation
The trial enrolled 119 patients with end-stage renal disease undergoing hemodialysis Final immunogenicity data anticipated in Q4 2020 EMERYVILLE, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Dynavax...
Dynavax to Present at the William Blair 40th Annual Growth Stock Conference
May 28, 2020 16:05 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 27, 2020 16:05 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock
May 21, 2020 21:00 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Technologies Announces Proposed Public Offering of Common Stock
May 21, 2020 16:01 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Announces First Quarter 2020 Financial Results
May 07, 2020 16:10 ET
|
Dynavax Technologies Corporation
Q1 2020 HEPLISAV-B® net product revenue of $10.5 million, compared to $5.6 million in Q1 2019Multiple collaborations established leveraging Dynavax’s vaccine adjuvant CpG 1018 in coronavirus...
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
April 28, 2020 16:10 ET
|
Dynavax Technologies Corporation
Demonstrated seroprotection rate of 86.4% at week 20 after 4 standard doses of HEPLISAV-BSafety data showed HEPLISAV-B was well toleratedCompany to host webinar review of data Thursday, April 30, 2020...
Dynavax to Report First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
April 23, 2020 16:10 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will...